Email: cspc@cspc.cn
Email: cspc@cspc.cn
R&D platform
R&D platform
The Group has established innovative R&D platforms which cover small molecules, macromolecules, nano-formulation, antibody-drug conjugates (ADC), mRNA vaccines and siRNA drugs, providing a solid foundation for the Group’s innovative research and development.
Nano-formulation
Mitoxantrone liposome
Albumin-bound docetaxel
Paclitaxel nanoparticles (instant type)
Cisplatin micelle
Features
State Key Laboratory of Novel Pharmaceutical Preparations and Excipients
Core technologies of independent intellectual properties and evaluation systems
The world's largest nano-formulation industrialization base
A total of more than 30 nano-preparations have been developed, 4 of which have been successfully launched
mRNA vaccine
Covid-19 mRNA vaccine
Rabies mRNA vaccine
Features
Integrating nanotechnology to form a complete chain of mRNA vaccine R&D
Breakthrough in key technical bottleneck for targeted delivery of nucleic acid drugs
A commercial vaccine production line has been put into operation
The first COVID-19 vaccine project for mutant strains has entered clinical phase
siRNA
PCSK9 siRNA
Features
Experienced and highly qualified nucleic acid drug R&D team
Focus on world-leading delivery technology
Screening globally competitive siRNA drugs for major disease areas
10 projects are under development, some of which showing pharmacodynamic advantages over foreign competitors
ADC
DP303c （HER2 ADC）
SYSA1801 (CLDN18.2 ADC)
Features
Enzymatic site-directed coupling technology with independent intellectual property rights
Linker technology for TME-specific activation
Next-generation ADC technologies such as bispecific ADCs, ISACs, and dual-payload molecular technologies
More than 10 ADC projects are under development, 3 of which are in clinical phase
BsAb
M701（EpCAM/CD3）
JMT601（CD47/CD20）
Features
World's leading asymmetric bispecific antibody platform developed independently
Targeted CD47 bifunctional fusion protein platform
The world's first bispecific SIRPα fusion protein technology platform with synergistic targeted binding effect.
More than 10 bispecific-antibody projects are under development, 5 of which are in clinical phase
Small molecule
JMT101 （EGFR）
JMT103（RANKL）
ALMB0168 (CX43 agonist)
ALMB0166 (CX43 inhibitor)
Features
Antibody screening platform based on various technologies such as phage, yeast, hybridoma, and mRNA
Antibody-directed engineering modification platform based on AI simulation technology
CMC development platform for a complete biological industry chain from DNA to BLA
More than 30 antibody and fusion protein projects are under development, at least10 of which are in clinical phase.
Antibodies and fusion proteins
SKLB1028 （FLT3）
SYHA1813 (VEGFR/CSF1R)
SYHA121-28 （RET TKI）
Features
Artificial Intelligence (AI) and Computer-Aided Drug Design (CADD) Technology Platform
300,000 compound libraries and 30 billion virtual molecular libraries
More than 40 small molecule projects are under development, at least 10 of which are in clinical phase
PROTAC
SYH2040
SYH2050
Features
Differentiated PROTAC protein degradation drug platform
Focus on "undruggable" targets
Good candidate compounds on multiple targets have been identified and have entered the IND research phase.
